Technology
Asahi Kasei bags breakthrough ADC tech in push for safer & more precise cancer therapies
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
- By IPP Bureau
| May 28, 2026
Asahi Kasei Life Science has acquired license rights to a next-generation antibody-drug conjugate (ADC) technology from The Noguchi Institute, in a significant move in the race to develop safer and more effective targeted therapies.
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs — a capability seen as a major advancement in improving treatment accuracy while reducing toxicity.
ADCs are among the fastest-growing classes of targeted biologics, combining the precision of antibodies with the power of cancer-killing payloads. Unlike conventional therapies, ADCs are designed to attack cancer cells more selectively while limiting damage to healthy tissue.
Built on The Noguchi Institute’s long-standing research into carbohydrates and glycans, the technology delivers superior molecular structure conformity, a feature expected to improve predictability in both drug efficacy and safety while supporting more stable therapeutic outcomes.
For Asahi Kasei Life Science, the deal strengthens its strategy of partnering with external innovators to accelerate future drug development opportunities. The platform’s ability to attach dual payloads to a single antibody could open the door to treating a wider range of diseases with greater specificity and potentially lower toxicity.
Under the agreement, the two organizations will work together to commercialize ADC drug platforms, including potential future sub-licensing opportunities for biopharma companies and Contract Development and Manufacturing Organizations (CDMOs) such as Bionova Scientific, an Asahi Kasei company.
The partnership will also include joint research efforts aimed at further refining the technology and expanding its potential to address unmet medical challenges.
